The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Next-generation sequencing (NGS) completion and timeliness using reflex testing protocol for patients with stage II-III non-squamous non-small cell lung cancer (NS-NSCLC).
 
Shipra Maheshwari
No Relationships to Disclose
 
Gordon Smilnak
No Relationships to Disclose
 
Rishika Singh
No Relationships to Disclose
 
Eli Williams
No Relationships to Disclose
 
Edward B Stelow
No Relationships to Disclose
 
Subodh Pandey
No Relationships to Disclose
 
Linda Martin
Consulting or Advisory Role - AstraZeneca; Genentech
Speakers' Bureau - Ethicon; Genentech
Research Funding - AstraZeneca
Other Relationship - On Target Laboratories
 
James Mitchell Larner
No Relationships to Disclose
 
Richard Delmar Hall
Consulting or Advisory Role - Jazz Pharmaceuticals; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Daiichi Sankyo/Lilly (Inst); Genentech; Lilly (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Regeneron (Inst)
 
Ryan D. Gentzler
Honoraria - Aptitude Health; Clinical Care Options; OncLive
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Janssen; Merus; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma; Janssen (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); RTI International (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Tempus